Table 2. Comparison of progression and non-progression in patients with BAD and LD.
| BAD | LD | |||||
| Progression | Non-progression | P | Progression | Non-progression | P | |
| N = 75 | N = 104 | N = 14 | N = 115 | |||
| Age, mean±SD | 64.31±13.32 | 62.58±11.29 | 0.363 | 68.50±12.71 | 65.43±12.21 | 0.379 |
| Gender, male, n (%) | 46(61.3) | 75(72.1) | 0.128 | 10(71.4) | 76(66.1) | 0.920 |
| CRP, median (IQR), mg/L | 2.9(1.7–8.4) | 2.11(0.90–5.28) | 0.025* | 2.95(1.68–7) | 2.7(1.26–5.2) | 0.552 |
| Hcy, mean±SD, umol/L | 15.90±7.00 | 13.15±4.74 | 0.004** | 15.75±6.17 | 16.14±8.73 | 0.872 |
| Hypertension, n (%) | 65(86.7) | 91(87.5) | 0.869 | 12(85.7) | 104(90.4) | 0.933 |
| Dyslipidemia, n (%) | 63(84.0) | 91(87.5) | 0.505 | 9(64.3) | 94(81.7) | 0.156 |
| Diabetes mellitus, n (%) | 37(49.3) | 40(38.4) | 0.147 | 6(42.9) | 43(37.4) | 0.691 |
| Smoking, n (%) | 23(30.7) | 33(31.7) | 0.880 | 3(21.4) | 38(33.0) | 0.564 |
| Ischemic heart disease, n (%) | 27(36.0) | 32(30.8) | 0.463 | 8(57.1) | 48(41.7) | 0.272 |
BAD, branch atheromatous disease; LD, lipohyalinotic degeneration; CRP, C-reactive protein; Hcy, Homocysteine; IQR, interquartile range; Progression, defined as worsening by ≥ 1 point in the NIHSS for motor function during the first 5 days.
*
P<0.05.
**
P<0.01.